The Ministry of Health's central buyer, founded in 1964, which procures and distributes medicines and equipment for public hospitals and clinics across Iraq. In 2019 it secured 60% of the essential medicines it is responsible for, and a short budget is named as a main cause of shortages.
The 2021 Eastern Mediterranean Health Journal report on pharmaceutical regulation in Iraq describes KIMADIA, founded in 1964, as the agency responsible for procuring and distributing medicines, medical appliances and equipment to public hospitals and primary care in all 18 provinces. It is required to procure the level 1 medicines on the national essential medicines list; where it cannot, provincial health directorates and hospitals may buy level 2 and then level 3 alternatives, or buy essential medicines from the private sector. In 2019 KIMADIA procured 60% of the level 1 essential medicines, and the report names an insufficient budget as one of the main reasons for shortages of essential medicines over several decades. KIMADIA can negotiate prices below the registered price in its tenders; national manufacturers held 15.3% of the value and 47.8% of the volume of its contracts in 2019. Public outpatient prescriptions cost the patient between 0.8 and 2.5 US dollars, according to the same report. The coordinates are a Baghdad city point.
Shares Pharmaceutical regulation in Iraq, from medicine approval to post-marketing, Directorate of Technical Affairs, Ministry of Health, Iraq (medicines regulator).
Shares Health Insurance Authority (Iraq), Directorate of Technical Affairs, Ministry of Health, Iraq (medicines regulator).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/